Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Ma...(p cell death. Unlike normal cells man...)

ability to undergo the normal process of programmed cell death, known

as apoptosis. CSP-9222 has demonstrated anti-tumor activity in a

range of pre-clinical animal tumor models, including taxane-resistant

tumors, following both intravenous and oral administration. The

Company expects to move this compound into Phase 1 clinical

development within 12-18 months. The caspase program was in-licensed

in August 2008 through an exclusive agreement with Bayer HealthCare

LLC; and

- OGX-225 aims to reduce the production of both Insulin-Like Growth

Factor Binding Protein -2 and Insulin-Like Growth Factor Binding

Protein -5 with a single product to enhance treatment sensitivity and

delay tumor progression. IGFBP-2 and IGFBP-5 are both hormones that

make an alternate hormone, IGF-1, available to the tumor that

facilitates continued tumor growth. Employing OGX-225 as a single

product to simultaneously inhibit the production of both IGFBP-2 and

IGFBP-5 has the potential to delay disease progression in a number of

cancers that are dependent upon IGF-1 for tumor growth. OGX-225 is in

pre-clinical development and has completed pre-clinical pharmacology.

About OncoGenex Pharmaceuticals, Inc.

OncoGenex Pharmaceuticals is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate currently completing five Phase 2 clinical studies in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associa
'/>"/>